Total Payments
$1.4M
2024 Payments
$380,301
Companies
28
Transactions
327
Medicare Patients
805
Medicare Billing
$116,004
Payment Breakdown by Category
Other$709,741 (50.4%)
Consulting$400,708 (28.4%)
Travel$149,968 (10.6%)
Research$122,597 (8.7%)
Food & Beverage$19,743 (1.4%)
Education$6,510 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $708,491 | 43 | 50.3% |
| Consulting Fee | $400,708 | 66 | 28.4% |
| Travel and Lodging | $149,968 | 84 | 10.6% |
| Unspecified | $122,597 | 76 | 8.7% |
| Food and Beverage | $19,743 | 48 | 1.4% |
| Education | $6,510 | 9 | 0.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,250 | 1 | 0.1% |
Payments by Type
General
$1.3M
251 transactions
Research
$122,597
76 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bristol Myers Squibb Company | $607,226 | 102 | $0 (2024) |
| SANOFI US SERVICES INC. | $218,925 | 7 | $0 (2019) |
| PFIZER INC. | $141,800 | 40 | $0 (2023) |
| CSL Behring | $111,970 | 42 | $0 (2024) |
| Janssen Research & Development, LLC | $71,250 | 8 | $0 (2022) |
| Boehringer Ingelheim International GmbH | $37,076 | 27 | $0 (2023) |
| Novo Nordisk AS | $31,656 | 8 | $0 (2022) |
| Boehringer Ingelheim Norway KS | $31,170 | 1 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $30,373 | 6 | $0 (2022) |
| Eli Lilly and Company | $30,036 | 10 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $380,301 | 48 | Bristol Myers Squibb Company ($365,901) |
| 2023 | $195,417 | 44 | Bristol Myers Squibb Company ($149,959) |
| 2022 | $327,392 | 101 | Bristol Myers Squibb Company ($91,366) |
| 2021 | $181,114 | 36 | PFIZER INC. ($51,540) |
| 2020 | $34,026 | 24 | CSL Behring ($17,000) |
| 2019 | $69,740 | 42 | PFIZER INC. ($16,200) |
| 2018 | $7,524 | 22 | Ironwood Pharmaceuticals, Inc ($4,200) |
| 2017 | $213,752 | 10 | SANOFI US SERVICES INC. ($205,286) |
All Payment Transactions
327 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Bristol Myers Squibb Company | — | Travel and Lodging | In-kind items and services | $463.27 | General |
| 12/31/2024 | Bristol Myers Squibb Company | — | Travel and Lodging | In-kind items and services | $424.43 | General |
| 12/31/2024 | Bristol Myers Squibb Company | — | Travel and Lodging | In-kind items and services | $328.30 | General |
| 12/31/2024 | Bristol Myers Squibb Company | — | Travel and Lodging | In-kind items and services | $283.31 | General |
| 12/20/2024 | Bristol Myers Squibb Company | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $35,000.00 | General |
| 12/10/2024 | Bristol Myers Squibb Company | — | Food and Beverage | Cash or cash equivalent | $430.79 | General |
| 12/10/2024 | Bristol Myers Squibb Company | — | Food and Beverage | Cash or cash equivalent | $262.43 | General |
| 11/16/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Cardiology | ||||||
| 10/10/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| 10/01/2024 | Bristol Myers Squibb Company | — | Travel and Lodging | In-kind items and services | $2,985.80 | General |
| 10/01/2024 | Bristol Myers Squibb Company | — | Travel and Lodging | In-kind items and services | $1,094.79 | General |
| 10/01/2024 | Bristol Myers Squibb Company | — | Travel and Lodging | In-kind items and services | $491.19 | General |
| 10/01/2024 | Bristol Myers Squibb Company | — | Travel and Lodging | In-kind items and services | $320.69 | General |
| 09/16/2024 | Bristol Myers Squibb Company | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $26,250.00 | General |
| 09/13/2024 | CSL Behring | — | — | Cash or cash equivalent | $3,000.00 | Research |
| Study: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome | ||||||
| 09/11/2024 | Bristol Myers Squibb Company | — | Travel and Lodging | In-kind items and services | $1,090.00 | General |
| 09/11/2024 | Bristol Myers Squibb Company | — | Food and Beverage | Cash or cash equivalent | $368.58 | General |
| 09/10/2024 | Bristol Myers Squibb Company | — | Food and Beverage | Cash or cash equivalent | $635.36 | General |
| 09/10/2024 | Bristol Myers Squibb Company | — | Food and Beverage | Cash or cash equivalent | $215.42 | General |
| 08/01/2024 | SANOFI-AVENTIS U.S. LLC | PRALUENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $250.00 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/21/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| 06/20/2024 | Bristol Myers Squibb Company | — | Food and Beverage | Cash or cash equivalent | $1,035.47 | General |
| 06/19/2024 | Bristol Myers Squibb Company | — | Travel and Lodging | In-kind items and services | $1,213.19 | General |
| 06/18/2024 | Bristol Myers Squibb Company | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $26,250.00 | General |
| 06/16/2024 | Bristol Myers Squibb Company | — | Travel and Lodging | In-kind items and services | $7,053.34 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome | CSL Behring | $62,000 | 19 |
| TOFACITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $20,710 | 18 |
| TOFACITINIB RA CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $19,720 | 14 |
| ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab | SANOFI-AVENTIS U.S. LLC | $7,345 | 15 |
| GOULD | Amgen Inc. | $7,049 | 3 |
| ERTUGLIFLOZIN CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,470 | 3 |
| ENVISAGE TAVI AF | Daiichi Sankyo Inc. | $1,000 | 1 |
| Primary 2-Year Results of GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Diseas | Amgen Inc. | $157.77 | 1 |
| (GOULD): a Registry of High Cardiovascular Risk Subjects in the United States | Amgen Inc. | $73.33 | 1 |
| Use of guideline-recommended risk-reduction strategies among patients with Type 2 diabetes and estab | Amgen Inc. | $71.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 9 | 268 | 287 | $226,116 | $40,970 |
| 2021 | 7 | 264 | 279 | $203,722 | $36,098 |
| 2020 | 9 | 273 | 280 | $209,590 | $38,937 |
Total Patients
805
Total Services
846
Medicare Billing
$116,004
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 92928 | Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | Facility | 2022 | 23 | 28 | $68,045 | $11,938 | 17.5% |
| 92941 | Removal of plaque and blood clot, insertion of stent and/or balloon dilation of single vessel | Facility | 2022 | 15 | 15 | $41,032 | $8,360 | 20.4% |
| 93458 | Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | Facility | 2022 | 33 | 35 | $42,700 | $6,807 | 15.9% |
| 93454 | Insertion of tube in coronary artery for diagnosis with review by radiologist | Facility | 2022 | 28 | 30 | $29,620 | $4,671 | 15.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 19 | 19 | $15,007 | $3,219 | 21.4% |
| 92978 | Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | Facility | 2022 | 29 | 32 | $11,913 | $2,565 | 21.5% |
| 93451 | Insertion of tube in right heart chambers for measurement | Facility | 2022 | 14 | 14 | $7,587 | $1,502 | 19.8% |
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Facility | 2022 | 93 | 100 | $4,906 | $1,052 | 21.5% |
| 93571 | Ultrasound evaluation of heart blood vessel during diagnosis or treatment, initial vessel | Facility | 2022 | 14 | 14 | $5,306 | $857.16 | 16.2% |
| 92928 | Catheter placement of stents in major coronary artery or branch, accessed through the skin, each additional artery or branch | Facility | 2021 | 26 | 35 | $85,330 | $15,611 | 18.3% |
| 93458 | Insertion of catheter in left heart for imaging of blood vessels and left lower heart including imaging interpretation and supervision and injection | Facility | 2021 | 35 | 35 | $42,735 | $6,415 | 15.0% |
| 93454 | Insertion of catheter for imaging of heart including imaging interpretation and supervision and injection | Facility | 2021 | 31 | 32 | $31,648 | $5,152 | 16.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 22 | 22 | $18,006 | $3,744 | 20.8% |
| 92978 | Ultrasound evaluation of heart blood vessel or graft, initial vessel | Facility | 2021 | 38 | 39 | $15,116 | $3,182 | 21.0% |
| 99152 | Moderate sedation services by physician also performing a procedure, patient 5 years of age or older, first 15 minutes | Facility | 2021 | 97 | 101 | $5,202 | $1,091 | 21.0% |
| 93571 | Ultrasound evaluation of heart blood vessel during diagnosis or treatment, initial vessel | Facility | 2021 | 15 | 15 | $5,685 | $902.95 | 15.9% |
| 92928 | Catheter insertion of stents in major coronary artery or branch, accessed through the skin | Facility | 2020 | 30 | 35 | $85,205 | $16,935 | 19.9% |
| 93458 | Insertion of catheter in left heart for imaging of blood vessels or grafts and left lower heart | Facility | 2020 | 30 | 30 | $36,630 | $5,581 | 15.2% |
| 93454 | Insertion of catheter for imaging of heart blood vessels or grafts | Facility | 2020 | 29 | 29 | $28,681 | $5,035 | 17.6% |
| 92978 | Ultrasound evaluation of heart blood vessel or graft | Facility | 2020 | 33 | 34 | $13,363 | $2,889 | 21.6% |
| 93460 | Insertion of catheter in right and left heart for imaging of blood vessels or grafts and left lower heart | Facility | 2020 | 11 | 11 | $16,999 | $2,527 | 14.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 11 | 11 | $8,922 | $1,969 | 22.1% |
| 93451 | Insertion of catheter for diagnostic evaluation of right heart structures | Facility | 2020 | 16 | 16 | $8,576 | $1,832 | 21.4% |
| 93571 | Ultrasound evaluation of heart blood vessel during diagnosis or treatment | Facility | 2020 | 16 | 17 | $6,443 | $1,117 | 17.3% |
| 99152 | Moderate sedation services by physician also performing a procedure, patient 5 years of age or older, first 15 minutes | Facility | 2020 | 97 | 97 | $4,771 | $1,052 | 22.0% |
About Dr. Deepak Bhatt, MD
Dr. Deepak Bhatt, MD is a Cardiovascular Disease healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1962515551.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Deepak Bhatt, MD has received a total of $1.4M in payments from pharmaceutical and medical device companies, with $380,301 received in 2024. These payments were reported across 327 transactions from 28 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($708,491).
As a Medicare-enrolled provider, Bhatt has provided services to 805 Medicare beneficiaries, totaling 846 services with total Medicare billing of $116,004. Data is available for 3 years (2020–2022), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Interventional Cardiology, Interventional Cardiology
- Location New York, NY
- Active Since 08/16/2006
- Last Updated 10/29/2025
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1962515551
Products in Payments
- SOTAGLIFLOZIN (Drug) $219,409
- XELJANZ (Drug) $137,330
- JARDIANCE (Drug) $37,700
- PRADAXA (Drug) $18,472
- BRILINTA (Drug) $11,976
- Non-Covered $11,052
- Kerendia (Drug) $7,526
- Repatha (Biological) $7,482
- XARELTO (Drug) $5,000
- STEGLATRO (Drug) $4,470
- PRALUENT (Biological) $4,444
- PRALUENT (Drug) $3,651
- Savaysa (Drug) $3,000
- KENGREAL (Drug) $388.72
- Victoza (Drug) $118.34
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in New York
Dr. Roger Hajjar, Md, MD
Cardiovascular Disease — Payments: $5.2M
Cardiovascular Disease $5.2M
Dr. Jacob Koruth, M.d, M.D
Cardiovascular Disease — Payments: $3.2M
Cardiovascular Disease $3.2M
Dr. Martin Leon, M.d, M.D
Cardiovascular Disease — Payments: $2.7M
Cardiovascular Disease $2.7M
Dr. Gregg Stone, M.d, M.D
Cardiovascular Disease — Payments: $2.2M
Cardiovascular Disease $2.2M
Adam Rosenbluth, Md, MD
Cardiovascular Disease — Payments: $1.5M
Cardiovascular Disease $1.5M
Dr. Philippe Genereux, M.d, M.D
Cardiovascular Disease — Payments: $1.1M
Cardiovascular Disease $1.1M